DongKook Pharmaceutical Co., Ltd. (086450.KQ)
KRW 15410.0
(0.46%)
KRW 15410.0
(0.46%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 1073.13 KRW | -10.83% |
| 2022 | 1203.46 KRW | 5.05% |
| 2021 | 1145.56 KRW | -9.98% |
| 2020 | 1272.52 KRW | -0.69% |
| 2019 | 1281.33 KRW | 19.94% |
| 2018 | 1068.27 KRW | 18.55% |
| 2017 | 901.10 KRW | -2.6% |
| 2016 | 925.17 KRW | 48.27% |
| 2015 | 623.99 KRW | 30.43% |
| 2014 | 478.40 KRW | 26.56% |
| 2013 | 378.00 KRW | -25.27% |
| 2012 | 505.80 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | 309.54 KRW | -31.43% |
| 2024 Q1 | 447.71 KRW | 117.11% |
| 2023 Q2 | 226.15 KRW | -38.0% |
| 2023 FY | - KRW | -10.83% |
| 2023 Q4 | 206.21 KRW | -25.29% |
| 2023 Q3 | 276.02 KRW | 22.05% |
| 2023 Q1 | 364.76 KRW | 71.21% |
| 2022 Q4 | 213.05 KRW | -20.75% |
| 2022 Q3 | 268.84 KRW | -26.22% |
| 2022 Q2 | 364.36 KRW | 2.0% |
| 2022 Q1 | 357.22 KRW | 1.86% |
| 2022 FY | - KRW | 5.05% |
| 2021 Q2 | 257.66 KRW | -25.13% |
| 2021 Q1 | 344.16 KRW | 70.38% |
| 2021 Q4 | 350.69 KRW | 81.66% |
| 2021 Q3 | 193.05 KRW | -25.08% |
| 2021 FY | - KRW | -9.98% |
| 2020 Q2 | 299.00 KRW | -18.97% |
| 2020 Q4 | 202.00 KRW | -46.98% |
| 2020 FY | - KRW | -0.69% |
| 2020 Q1 | 369.00 KRW | -0.54% |
| 2020 Q3 | 381.00 KRW | 27.42% |
| 2019 Q2 | 271.80 KRW | -2.65% |
| 2019 FY | - KRW | 19.94% |
| 2019 Q1 | 279.20 KRW | -11.3% |
| 2019 Q4 | 371.00 KRW | 10.09% |
| 2019 Q3 | 337.00 KRW | 23.99% |
| 2018 Q2 | 242.93 KRW | 3.91% |
| 2018 Q4 | 314.76 KRW | 17.71% |
| 2018 Q3 | 267.40 KRW | 10.07% |
| 2018 FY | - KRW | 18.55% |
| 2018 Q1 | 233.80 KRW | -19.82% |
| 2017 Q1 | 186.21 KRW | -27.49% |
| 2017 Q4 | 291.58 KRW | 41.0% |
| 2017 Q3 | 206.80 KRW | -4.44% |
| 2017 Q2 | 216.40 KRW | 16.21% |
| 2017 FY | - KRW | -2.6% |
| 2016 FY | - KRW | 48.27% |
| 2016 Q2 | 226.20 KRW | 18.05% |
| 2016 Q1 | 191.61 KRW | -3.52% |
| 2016 Q4 | 256.79 KRW | 2.47% |
| 2016 Q3 | 250.60 KRW | 10.79% |
| 2015 Q2 | 118.99 KRW | -2.47% |
| 2015 Q1 | 122.00 KRW | 20.86% |
| 2015 Q3 | 184.40 KRW | 54.97% |
| 2015 Q4 | 198.60 KRW | 7.7% |
| 2015 FY | - KRW | 30.43% |
| 2014 Q3 | 144.20 KRW | 36.46% |
| 2014 Q4 | 100.94 KRW | -30.0% |
| 2014 FY | - KRW | 26.56% |
| 2014 Q1 | 127.56 KRW | 290.45% |
| 2014 Q2 | 105.67 KRW | -17.16% |
| 2013 Q4 | 32.67 KRW | -79.16% |
| 2013 FY | - KRW | -25.27% |
| 2013 Q1 | 110.13 KRW | -27.76% |
| 2013 Q2 | 75.41 KRW | -31.53% |
| 2013 Q3 | 156.80 KRW | 107.93% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q4 | 152.44 KRW | -7.5% |
| 2012 Q3 | 164.80 KRW | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -666.05 KRW | 261.119% |
| CMG Pharmaceutical Co., Ltd. | 46.00 KRW | -2232.891% |
| Celltrion Pharm, Inc. | 539.00 KRW | -99.096% |
| Huons Global Co., Ltd. | 3133.85 KRW | 65.757% |
| Enzychem Lifesciences Corporation | -109.81 KRW | 1077.261% |
| Humedix Co., Ltd. | 2512.11 KRW | 57.282% |
| Boditech Med Inc. | 1181.00 KRW | 9.134% |
| EuBiologics Co., Ltd. | -381.00 KRW | 381.661% |
| FutureChem Co.,Ltd | -303.61 KRW | 453.457% |
| Huons Co., Ltd. | 4261.00 KRW | 74.815% |
| BNC Korea Co., Ltd. | 388.00 KRW | -176.58% |
| AptaBio Therapeutics Inc. | -540.91 KRW | 298.393% |